Making Medicine

From the JP Morgan Conference: The Impact of the Inflation Reduction Act

John was at the JP Morgan conference and is here to discuss the key takeaways of the Inflation Reduction Act: the small-molecule penalty, the value of small-molecule drugs, the importance of incentivizing post-approval research, intellectual property, and non-coverage decisions at CMS. You’ll also hear John’s take on the demand for a more pro-patient agenda. There was a lot of focus on the role of policy and government, specifically in relation to the inflation reduction act and its impact on the life science and venture capital industries. Ready to reaffirm its values, Incubate will be focusing its energy on working with the White House and Congress to make necessary amendments to the legislation. They’ll also have a focus on education and awareness to ensure that policymakers understand the critical role they play in the healthcare landscape. Join us as we discuss: * Why is there excitement for 2023 in the biotech sector, but also some anxiety? * How does the organization, Incubate, plan to address the inflation reduction act? * What Congress can be doing to create a more pro-patient agenda?

Drug Investment Under the Inflation Reduction Act

How will the Inflation Reduction Act affect life sciences startups, current and future revenues, and drug investment? What will happen to patients amidst the aftermath of unintended consequences? There aren’t too many people who know more about the ins and outs than the fine folks at DLA Piper. One of the biggest interventions in drug pricing since the Medicare Modernization Act was passed, listen to the inside scoop on what this means for the future of drugs. Join us as we discuss: -What drug price negotiations will look like under the act -How brand competition will play out -Which drugs and stakeholders will be affected

The Three Pillars of Bio & Med Tech Investing and Industry Impact of DEI

When you’re working to make good investments in bio and med tech there are three key pillars to consider: science, the management team and finance. But how does it all come together in the end? Find out in the latest episode with Christine Brennan, Managing Director, Vertex Venture HC as we talk about Vertex’s investment philosophy, why DEI inclusion is vital for industry, and what investments could look like for the rest of 2022. Join us as we discuss: Christine’s journey to becoming the Managing Director at Vertex The investment firm’s philosophy around Bio Tech, therapeutic investments and MedTech Why it’s so important for the next generation to have women in tech As we continue this journey together, we want to hear from you, the listener. Email John@incubatecoalition.org [John@incubatecoalition.org] or Ashlyn@incubatecoalition.org [Ashlyn@incubatecoalition.org] what’s top of mind, what story you want to hear, or what you find interesting! To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.

Understanding Health Equity w/ Dr. Jerome Adams

Everyone wants to make healthy choices. But we don't always have an opportunity to make healthy choices. In today’s episode, we speak with Dr. Jerome Adams, Executive Director of Health Equity Initiatives at Purdue University and the 20th Surgeon General of the United States, about the need for proactive accessible health care, the economic burden of inaccessible healthcare, and why people need to know you care, before they care about what you know As we continue this journey together, we want to hear from you, the listener. Email John@incubatecoalition.org [John@incubatecoalition.org] or Ashlyn@incubatecoalition.org [Ashlyn@incubatecoalition.org] what’s top of mind, what story you want to hear, or what you find interesting! To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.

Addressing The Overlooked AMR Problem w/ Dr. Henry Skinner

Investors are logical people. They invest in medicines that they expect will give them a return. Right now, there’s far too little investment in developing new antibiotics. The pipeline of treatment is thin, but the need is greater than ever. Enter the AMR Action Fund. Hear our conversation with Dr. Henry Skinner, Chief Executive Officer at AMR Action Fund about: The increasing cost of AMR and policy challenges How to build the pipeline to reach the new antibiotics we need to save millions Leveraging healthcare innovation for AMR before it’s too late AMR Action Fund’s first two investments and future outlook More information about Henry and today’s topics: LinkedIn Profile: http://www.linkedin.com/in/henryskinner/ [http://www.linkedin.com/in/henryskinner/] Company Website: https://www.amractionfund.com [https://www.amractionfund.com]/ As we continue this journey together, we want to hear from you, the listener. Email John@incubatecoalition.org [John@incubatecoalition.org] or Ashlyn@incubatecoalition.org [Ashlyn@incubatecoalition.org] what’s top of mind, what story you want to hear, or what you find interesting! To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.